A Nasdaq Hearings Panel granted Silexion continued listing, subject to conditions. The company must complete a $2.5 million private placement by December 4, 2026, and a public offering of at least $5 million by March 31, 2027.
SLXN · Silexion Therapeutics Corp
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, we had cash and cash equivalents of $4.8 million. Based on our current cash balance, as well as our history of operating losses and negative cash flows from operations, combined with our anticipated use of cash to, among other things, (i) fund the clinical development of SIL204, (ii) identify and develop new product candidates, and (iii) seek approval for SIL204 and any other product candidates we may develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and nine-month periods ended September 30, 2026 included in this quarterly report, but rather, for only several months from the filing date of this quarterly report, under our current business plan, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 54%
- Latest filing
- 10-Q · Nov 12
- Price history
- Apr 2021 to Nov 2026
Latest documents
Silexion Therapeutics Corp dosed its first patient with SIL204 on September 30, 2026 in a Phase 2/3 pancreatic cancer trial at Tel Aviv Sourasky Medical Center. Cash and cash equivalents were $4.8 million.
Silexion Therapeutics Corp dosed its first SIL204 Phase 2/3 patient in locally advanced pancreatic cancer, while awaiting a Nasdaq listing decision. The company reported an $8.8 million nine-month net loss and said cash would fund only several months.
Silexion Therapeutics Corp completed a 1-for-24 reverse share split effective after trading on November 10, 2026, leaving 21,495,833 authorized ordinary shares at $3.24 par value and adjusting warrants to 1/24 share each at $372,600.00 per share.
Silexion Therapeutics Corp will conduct a 1-for-24 reverse share split after market close on November 10, 2026, with split-adjusted Nasdaq Capital Market trading beginning November 11, 2026 under ticker “SLXN”; par value will rise from $0.135 per share to $3.24 per share.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| gross proceeds | $1.9M | third quarter | — |
| ATM net proceeds | $1.8M | the third quarter of 2026 filing | — |
|
|
|||
| ordinary shares sold under ATM program, net of sales agent fees and issuance costs | $1.8M | the third quarter of 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLXN
this stock
Silexion Therapeutics Corp
|
$974,292 | — | — | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 507.5%
- Net QoQ
- +874.7K sh
- Top holder
- BANK OF MONTREAL /CAN/
- Filed
- Nov 19, 2026
- This year
- 59
A Nasdaq Hearings Panel granted Silexion continued listing, subject to conditions. The company must complete a $2.5 million private placement by December 4, 2026, and a public offering of at least $5 million by March 31, 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLXN | -43.6% | -62.1% | -98.7% | -56.9% | -99.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -38.2% | -55.8% | -93.1% | -51.6% | -104.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.